Tesamorelin for belly fat: separating FDA data from hype

What did @atruediamond24 actually say?

The creator gave a general overview of tesamorelin, calling it "the body composition peptide" and an "FDA approved growth hormone peptide" approved in 2010 under the brand name Egrifta for HIV-associated lipodystrophy. They described it as a growth hormone secretagogue that stimulates the pituitary gland, promotes lipolysis, and targets visceral fat. They also claimed benefits including increased libido, improved skin, mood support for depression and anxiety, immune support, and cognitive function. On the practical side, they advised taking it subcutaneously at night on an empty stomach, recommended combining it with ipamorelin to reduce side effects, and listed joint pain, water retention, and injection site reactions as potential side effects.

Does the science back this up?

The core mechanism and the FDA approval history are largely accurate. The benefits list, though, runs well ahead of what the evidence actually supports for most users.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Its FDA approval for HIV-associated lipodystrophy is real, and the clinical trials behind it are solid. Falutz et al. (2010, The Lancet) demonstrated significant reductions in visceral adipose tissue (VAT) in HIV-positive patients after 26 weeks of treatment, with mean VAT reductions around 18 percent compared to placebo. The lipolysis claim is mechanistically sound: growth hormone stimulates hormone-sensitive lipase activity, preferentially mobilizing visceral fat.

The claims about libido, skin, depression, anxiety, and immune support are where things get shaky. These are extrapolated from general growth hormone physiology rather than tesamorelin-specific controlled trials in healthy or non-HIV populations. Stanley et al. (2012, NEJM) showed cognitive benefits in HIV patients, but generalizing that to healthy adults is a stretch the evidence does not currently support.

What did they get wrong (or right)?

They got the FDA history right. They got the mechanism largely right. They spelled the brand name wrong (it is Egrifta, not Agryfta), but that is a minor error.

The bigger problem is the benefits list. Saying tesamorelin "increases libido," is "good for depression and anxiety," and supports immune function presents speculative or indirect evidence as established fact. These claims ride on general GH physiology, not tesamorelin trial data in otherwise healthy adults. That is a meaningful distinction when you are advising 11,000 people.

The ipamorelin recommendation also deserves scrutiny. Combining peptides is common practice in optimization communities, but there are no published controlled trials evaluating the tesamorelin-ipamorelin stack for safety or efficacy. The claim that ipamorelin "decreases the side effects" of tesamorelin is unverifiable from current published literature.

The dosing advice, taking it subcutaneously at night on an empty stomach, is directionally consistent with clinical practice guidance, but giving injection instructions to a general TikTok audience without a prescriber conversation is exactly the kind of thing that creates problems. Credit where it is due: they at least acknowledged side effects and said they do not apply to everyone.

What should you actually know?

Tesamorelin is one of the few peptides that actually has a well-designed clinical trial record. That matters. Most peptides discussed in this category have thin or nonexistent human data. Tesamorelin does not.

But its approval is narrow. The FDA approved it specifically for HIV-associated lipodystrophy, not for general fat loss, anti-aging, or body composition in otherwise healthy people. Off-label use happens, but it carries different risk and regulatory considerations than on-label use. Compounded versions are not equivalent to FDA-approved Egrifta, and the FDA has previously raised concerns about compounded tesamorelin. Anyone considering this drug should be doing so under the supervision of a licensed prescriber who can evaluate cardiovascular risk, glucose tolerance (tesamorelin can worsen insulin sensitivity), and potential contraindications. Lorentzen et al. (2021, JCEM) noted glucose metabolism changes as a clinically relevant concern in non-HIV populations. That detail did not make the video.